Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.79 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | QPCT | Q16769 | 1/20 | 0.53 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1677835 | 0.83 | HRH4 (0.57) | HRH4HRH3MEN1ALDH1A1MAPT | |
| SCHEMBL13073926 | 0.80 | HRH3 (0.77) | HRH4HRH3MEN1ALDH1A1MAPT | |
| SCHEMBL13337048 | 0.79 | HRH3 (0.78) | HRH4HRH3MEN1ALDH1A1MAPT | |
| SCHEMBL3934417 | 0.77 | HRH3 (0.61) | HRH4HRH3MEN1ALDH1A1MAPT | |
| SCHEMBL14569277 | 0.76 | CYP19A1 (0.57) | HRH4HRH3MEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1696889 | 0.74 | HRH3 (0.96) | HRH4HRH3MEN1ALDH1A1MAPT | |
| SCHEMBL26267985 | 0.73 | HRH3 (0.72) | HRH4HRH3MEN1ALDH1A1MAPT | |
| SCHEMBL21290462 | 0.72 | HRH4 (0.45) | HRH4HRH3ALDH1A1 | |
| SCHEMBL14197099 | 0.72 | QPCT (0.69) | HRH4HRH3MEN1ALDH1A1MAPT | |
| SCHEMBL8963903 | 0.72 | HRH3 (0.73) | HRH4HRH3MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | HRH4 3192/4885HRH3 1617/4885MEN1 1157/4885 |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | HRH4 2441/4885HRH3 3867/4885MEN1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.